Clinical trial
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
NCT06510283 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
- Lead sponsor
- Beijing Tongren Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 1, 2024
- Completion date
- July 1, 2028
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.